Lyell Immunopharma Valuation
| LYEL Stock | USD 0.92 0.01 1.10% |
Today, the firm appears to be fairly valued. Lyell Immunopharma secures a last-minute Real Value of $0.89 per share. The latest price of the firm is $0.92. Our model forecasts the value of Lyell Immunopharma from analyzing the firm fundamentals such as Current Valuation of (132.08 M), shares owned by insiders of 14.06 %, and Return On Equity of -0.33 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Lyell Immunopharma's valuation include:
Price Book 0.4843 | Enterprise Value -132.1 M | Enterprise Value Ebitda 0.251 | Price Sales 4.1 K | Enterprise Value Revenue 1.9 K |
Fairly Valued
Today
Please note that Lyell Immunopharma's price fluctuation is abnormally volatile at this time. Calculation of the real value of Lyell Immunopharma is based on 3 months time horizon. Increasing Lyell Immunopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Lyell stock is determined by what a typical buyer is willing to pay for full or partial control of Lyell Immunopharma. Since Lyell Immunopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Lyell Stock. However, Lyell Immunopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.92 | Real 0.89 | Target 7.0 | Hype 0.92 |
The intrinsic value of Lyell Immunopharma's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Lyell Immunopharma's stock price.
Estimating the potential upside or downside of Lyell Immunopharma helps investors to forecast how Lyell stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lyell Immunopharma more accurately as focusing exclusively on Lyell Immunopharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Lyell Immunopharma's intrinsic value based on its ongoing forecasts of Lyell Immunopharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Lyell Immunopharma's closest peers.
Lyell Immunopharma Cash |
|
Lyell Valuation Trend
Knowing Lyell Immunopharma's actual value is paramount for traders when making sound investment determinations. Using both Lyell Immunopharma's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Lyell Immunopharma Total Value Analysis
Lyell Immunopharma is now forecasted to have valuation of (132.08 M) with market capitalization of 257.02 M, debt of 63.17 M, and cash on hands of 655.56 M. The negative valuation of Lyell Immunopharma may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Lyell Immunopharma fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(132.08 M) | 257.02 M | 63.17 M | 655.56 M |
Lyell Immunopharma Investor Information
About 14.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.48. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Lyell Immunopharma has Price/Earnings To Growth (PEG) ratio of 0.68. The entity recorded a loss per share of 0.79. The firm had not issued any dividends in recent years. Based on the key measurements obtained from Lyell Immunopharma's financial statements, Lyell Immunopharma may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Lyell Immunopharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Lyell Immunopharma has an asset utilization ratio of 0.0173 percent. This suggests that the Company is making $1.73E-4 for each dollar of assets. An increasing asset utilization means that Lyell Immunopharma is more efficient with each dollar of assets it utilizes for everyday operations.Lyell Immunopharma Ownership Allocation
Lyell Immunopharma maintains a total of 279.22 Million outstanding shares. Over half of Lyell Immunopharma's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Lyell Immunopharma Profitability Analysis
The company reported the previous year's revenue of 130 K. Net Loss for the year was (234.63 M) with profit before overhead, payroll, taxes, and interest of 84.68 M.About Lyell Immunopharma Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Lyell Immunopharma. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Lyell Immunopharma based exclusively on its fundamental and basic technical indicators. By analyzing Lyell Immunopharma's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Lyell Immunopharma's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Lyell Immunopharma. We calculate exposure to Lyell Immunopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Lyell Immunopharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 130 K | 123.5 K | |
| Pretax Profit Margin | -1.8 K | -1.7 K | |
| Operating Profit Margin | -1.9 K | -1.8 K | |
| Net Loss | -1.8 K | -1.7 K | |
| Gross Profit Margin | 0.72 | 0.76 |
Lyell Immunopharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Lyell Immunopharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 251 M |
Lyell Immunopharma Current Valuation Indicators
Lyell Immunopharma's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Lyell Immunopharma's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Lyell Immunopharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Lyell Immunopharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Lyell Immunopharma's worth.When determining whether Lyell Immunopharma is a strong investment it is important to analyze Lyell Immunopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lyell Immunopharma's future performance. For an informed investment choice regarding Lyell Stock, refer to the following important reports: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.79) | Quarterly Revenue Growth 0.36 | Return On Assets (0.19) | Return On Equity (0.33) |
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.